Compare Consolidated Edison, Inc. (ED) vs Pfizer Inc (PFE) Price & Performance

Consolidated Edison (ED) trades at $111.58, down 0.32% on the day, with a bullish technical signal and strong fundamental performance. The utility company reported Q3 and Q4 2025 earnings beats but missed Q1 2026 estimates, with Q2 2026 results due August 6. ED maintains solid profitability with 12.52% net income margin and $2.02B net income in 2025, supported by $4.8B operating cash flow. Recent news highlights grid upgrades for AI data center demand and electric school bus fleet expansion.

ED offers stable dividend income with a 3.3% yield and 52-year growth streak, but faces mixed analyst sentiment (62.96% hold rating) and consensus price target of $103.50 below current price. Key risks include rising interest expenses ($1.23B in 2025) and capital-intensive grid modernization. The stock presents value for income investors despite near-term execution challenges.

Pfizer (PFE) trades at $24.25, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported $62.58B in 2025 revenue and a net income margin of 11.83%, with recent quarterly earnings consistently beating expectations. A dividend of $0.43 per share is scheduled for payment on September 1, 2026. The stock's valuation includes a P/E of 18.51 and P/S of 2.19, while analyst consensus price target is $28.25.

Pfizer presents a mixed outlook with stable profitability and a strong dividend, but faces headwinds from patent expirations and competitive pressures. The stock offers value at current levels relative to analyst targets, though technical weakness and revenue declines from peak COVID-era sales pose near-term risks for investors.